In Brief: Quigley
This article was originally published in The Tan Sheet
Quigley: Purchase orders for Cold-Eeze zinc lozenges have reached $12.5 mil., the Doylestown, Penn. firm states Jan. 15. The manufacturer of the homeopathic cold product had announced a $3.5 mil. backlog in December, noting at the time its plans for expansion of its manufacturing facilities ("The Tan Sheet" Dec. 9, 1996, In Brief). With its increased manufacturing capacity, Quigley plans to produce around $1.5 mil. of Cold-Eeze per week. The company recently announced an anticipated $3.9 mil. in revenues and net earnings of $1.8 mil. for the first quarter ended Dec. 31. For the fiscal year ended Sept. 30, Quigley reported revenues of $1 mil. and a loss of $694,269, compared to $501,903 in revenues and a $152,556 loss in the previous fiscal year. Also, Quigley announced Jan. 17 that it has requested an investigation by the Securities & Exchange Commission into "attempts to discredit the company through fake press releases to the media and incorrect information posted on the Internet"...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: